Lilly Enhances Manufacturing Investment to $9 Billion To Boost API Production

Eli Lilly & Company stated that it has more than quadrupled its investment in its Lebanon, Indiana, production location, with a fresh $5.3 billion commitment, bringing the total investment to $9 billion. This expansion will increase Lilly's ability to produce active pharmaceutical ingredients (API) for Zepbound® (tirzepatide) injectable and Mounjaro® (tirzepatide) injection, allowing more adults with chronic conditions including obesity and type 2 diabetes to benefit from these critical therapies.

Since 2020, Lilly has pledged more than $16 billion to establish new production facilities in the United States and Europe. New locations outside of Indiana include Research Triangle Park in Concord, North Carolina; Limerick, Ireland; and Alzey, Germany. Separately, the business has invested an additional $1.2 billion to upgrade existing manufacturing facilities in Indianapolis, and it just purchased an injectable manufacturing facility in Pleasant Prairie, Wisconsin, from Nexus Pharmaceuticals. These manufacturing investments amount over $18 billion.

"Today's announcement tops the largest manufacturing investment in our company's history and, we believe, represents the single largest investment in synthetic medicine API manufacturing in U.S. history," said David A. Ricks, Lilly's chair and CEO. "This multi-site campus will make our latest medicines, including Zepbound and Mounjaro, support pipeline growth and leverage the latest technology and automation for maximum efficiency, safety and quality control. Importantly, we are investing in our home state of Indiana, creating high-wage, advanced manufacturing, engineering and science jobs for hundreds of current and future Hoosier families."